There is a considerable interest in developing potent and safe hypolipidemic drugs for the prevention and management of coronary heart disease in man. In rodents, many of these hypolipidemic compounds induce hepatomegaly, proliferation of peroxisomes and a polypeptide with an approximate mol. wt. of 80000 in liver cells. In the present study, we have examined 10 hypolipidemic compounds for the induction of peroxisome proliferation associated 80000 mol. wt. polypeptide (polypeptide PPA-80), peroxisomal enzymes and peroxisome proliferation in rat liver, in view of the emerging evidence that hepatic peroxisome proliferators as a class are carcinogenic in rats and mice. All ten compounds, fenofibrate (isopropyl-[4-( p-chlorobenzoyl)2-phenoxy-2-methyl] propionate; LS 2265 (taurine derivative of fenofibrate); bezafibrate (2-{4-(2-[4-chlorobenzamido)ethyl] phenoxy}-methyl propionic acid; gemfibrozil (5-2[2,5-dimethylphenoxy]2-2-dimethylpentanoic acid); methyl clofenapate (methyl-2-[4-(p-chlorophenyl)phenoxy]-2-methyl propionate); DG 5685 (5-[4-phenoxybenzyl]trans-2-(3-pyridyl)1,3-dioxane), DH6463 (5-[4-phenoxybenzyl] trans-2-(3-pyrimidinyl)-1,3-dioxane); tiadenol(bis[hydroxyethylthio]-7, 10-decane); ciprofibrate (2,-[4-{2,2-dichlorocyclopropyl}-phenoxy]2-methyl propionic acid) and RMI-14,514 ([5-tetradecycloxyl-2-furancarboxylic acid), produced a marked but variable increase in the activities of peroxisomal enzymes catalase, carnitine acetyltransferase, heat-labile enoyl-CoA hydratase and the fatty acid β-oxidation system and in the amount of polypeptide PPA-80 as demonstrated by SDS-polyacrylamide gel electrophoresis. The peptide map patterns of polypeptide PPA-80 in liver induced by these compounds were strikingly similar. The ultrastructural studies demonstrate that fenofibrate, ciprofibrate, LS 2265, DG 5685 and DH 6463 can induce proliferation of peroxisomes in liver cells of rats, and further confirm the previous reports of hepatic peroxisome proliferative activity of methyl clofenapate, tiadenol, bezafibrate, gemfibrozil and RMI-14514, as shown morphologically. Whether these structurally unrelated chemicals or their metabolite(s) directly activate the peroxisome specific genes to induce this multi-enzyme system or they exert their action on peroxisomes indirectly by causing fatty acid overload in hepatocytes remains to be elucidated. These chemicals offer a simple and reproducible means of stimulating peroxisomal enzymes in liver and should serve as useful tools, for evaluating the implications of hepatic peroxisome proliferation and in elucidating the mechanism of peroxisome proliferator-induced carcinogenesis.
Get full access to this article
View all access options for this article.
References
1.
Ames, B.N. (1981). Lipid peroxidation and oxidative damage to DNA . In Lipid Peroxide in Biology and Medicine (K. Yagi, ed.). New York, Academic Press.
2.
Arnold, A., McAulief, J.P., Powers, L.G., Phillips, D.K. & Beyler, A.L. (1979). The results of animal studies with ciprofibrate, a new orally effective hypolipidemic drug. Atherosclerosis , 32, 155-163.
3.
Bencze, W.L. (1978). New hypolipidemic drugs. In 6th International Symposium on Drugs Affecting Lipid Metabolism, Philadelphia, 1977 (D. Kritchevsky , R. Paolletti, & W. L. Paoletti, eds.) pp. 77-95. New York, Plenum Press.
4.
Cleveland, D.W., Fischer, S.G., Kirschner, M.W. & Laemmli, U.K. (1977). Peptide mapping by limited proteolysis in sodium dodecylsulfate and analysis by gel electrophoresis. J. Biol. Chem., 252,1102-1106.
5.
Committee Of Principal Investigators. (1978 ). A cooperative trial in the primary prevention of ischaemic heart disease using clofibrate. Brit. Heart J., 40, 1069-1118.
6.
Cooper, T.G. & Beever, H. (1969). β-oxidation in glyoxsomes from castor bean endosperm. J. Biol. Chem., 244, 3514-3520.
7.
de laIglesia, F.A. & Farber, E. (1981). Hepatocarcinogenesis of hypolipidemic agents. Gen. Pharmacol., 12, 25. (Abstract).
8.
de la Iglesia, F.A., Pinn, S.M., Lucas, J. & McGure, E.J. (1981). Quantitative stereology of peroxisomes in hepatocytes from hyperlipoproteinemic patients receiving gemfibrozil. Micron., 12, 97-98.
Fahimi, H.D., Kalmbach, P., Steigmeier, L. & Stork, H. (1980). Comparison between the effects of clofibrate and bezafibrate upon the ultrastructure of rat heart and liver. In Lipoproteins and coronary heart diseases ( H. Greten, P. D. Lang & G. Schetter, eds.) pp. 64-75. New York, G. Witzstroch.
13.
Finkel, M.J. (1977). FDA considerations regarding new hypolipidemic agents. Lipids, 12, 64-65.
14.
Fritz, I.B., Schultz, S.K. & Spere, P.A. (1963). Properties of partially purified carnitine acetyltransferase . J. Biol. Chem., 238, 2509-2517.
15.
Fukuda, K., Shindo, H., Yamashin, S. & Mizuhira, V. (1978). Fine structural changes in hepatic microbodies of rats treated with hypolopodemic agents gemfibrozil and clofibrate. Acta. Histol., 11, 432-442.
16.
Hanefeld, M., Kemmer, C., Leonhardt, W., Kunze, K.D., Jaross, W. & Haller, H. (1980). Effects of p-chlorophenoxyisobutyric acid (CPIB) on the human liver. Atherosclerosis, 36, 159-172.
17.
Havel, R.J. & Kane, J.P. (1973). Drugs and lipid metabolism. Ann. Rev. Pharmacol., 13, 287-308.
18.
Hayashi, H., Hino, S., Yamasaki, F., Watanabe, T. & Suga, T. (1981). Induction of peroxisomal enzymes in rat liver by the hypolipidemic agent LK-903. Biochem. Pharmacol., 30, 1817-1822.
19.
Hess, R., Staubli, W. & Reiss, W. (1965). Nature of the hepatomegalic effect produced by ethyl-chlorophenoxyisobutyrate in the rat. Nature, 208, 856-858.
20.
Hruban, Z., Gotoh, M., Slesers, A. & Chau S.-F. (1974). Structure of hepatic microbodies in rats treated with acetylsalicylic acid, clofibrate and dimethrin. Lab. Invest., 30, 64-75.
21.
Kahonen, M.T. & Ylikahri, R.H. (1979). Effect of clofibrate and gemfibrozil on the activities of mitochondrial carnitine acyltransferases in rat liver. Dose-response relation. Atherosclerosis, 32, 47-56.
22.
Kariya, T., Parker, R.A., Grisar, J.M., Martin, J. & Wille, L.J. (1975). Laboratory studies with RMI-14,514 a new hypolipidemic agent. Fed. Proc., 34, 789. (Abstract.)
23.
Kritchevsky, D. (1980). Twenty years of DALM—where do we stand? In Drugs Affecting Lipid Metabolism ( R. Fumagalli, D. Kritchevsky & R. Paoletti, eds.). pp. 1-71. Amsterdam , Elsevier/North Holland Biomedical Press.
24.
Kurtz, S.M., Fitzgerlad, J.E., Fisken, R.A., Schardein, J.L., Reutner, T.H. & Lucas, J.A. (1976). Toxicological studies on gemfibrozil. Proc. Roy. Soc. Med., 69,15-23.
25.
Kurup, C.K.R., Atthal, H.N. & Ramasarma, T. (1970). Increase in hepatic mitochondria on administration of ethyl-α-p-chloro-phenoxyisobutyrate to the rat. Biochem. J., 116, 773-779.
26.
Laemmli, U.K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 227, 680-685.
27.
Lalwani, N.D., Reddy, M.K., Mark, M.M. & Reddy, J.K. (1981a). Induction, immunochemical identity and immunofluorescence localization of peroxisome proliferation associated polypeptide (PPA-80) and peroxisomal enoyl-CoA hydratase of mouse liver and renal cortex. Biochem. J., 198, 177-186.
28.
Lalwani, N.D., Reddy, M.K., Qureshi, S.A. & Reddy, J.K. (1981b). Development of hepatocellular carcinomas and increased peroxisomal fatty acid β-oxidation in rats fed [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14,643) in the semipurified diet. Carcinogenesis , 2, 645-650.
29.
Lazarow, P.B. (1977). Three hypolipidemic drugs increase hepatic palmitoyl coenzyme A oxidation in the rat. Science, 197, 580-581.
30.
Lazarow, P.B. (1978). Rat liver peroxisomes catalyse the β-oxidation of fatty acids. J. Biol. Chem., 253,1522-1528.
31.
Lazarow, P.B. (1980). Elevation of peroxisomal β-oxidation by bezafibrate . In Lipoproteins and Coronary Heart Diseases (H. Greten, P. D. Long & G. Schettler, eds.). pp. 96-100. New York, G. Witzstrock.
32.
Lazarow, P.B. & deDuve, C. (1976). A fatty acyl-CoA oxidizing system in rat liver peroxisomes; enhancement by clofibrate, a hypolipidemic drug. Proc. Natl. Acad. Sci. USA, 73, 2043-2046.
33.
Lowry, O.H., Rosebrough, N.J., Farr, A.L. & Randall, R.J. (1951). Protein measurement with the folin-phenol reagent . J. Biol. Chem., 193, 265-275.
34.
Luck, H. (1965). Catalase. In Methods of Enzymatic Analysis. (H.U. Bergmeyer, ed.). pp. 885-888. New York, Academic Press.
35.
Markwell, M.A.K., McGroaty, E.J., Bieber, L.L. & Tolbert, N.E. (1973). The subcellular distribution of carnitine acetyl transferases in mammalian liver and kidney. A new peroxisomal enzyme. J. Biol. Chem., 248, 3426-3432.
36.
Markwell, M.A.K., Bieber, L.L. & Tolbert, E. (1977). Differential increase of hepatic peroxisomal, mitochondrial and microsomal carnitine acetyl transferases in clofibrate fed rat. Biochem. Pharmacol., 26,1697-1702.
37.
Mittal, B. & Kurup, C.K.R. (1981). Induction of carnitine acetyl transferase by clofibrate in rat liver. Biochem. J., 194, 249 -255.
38.
Moody, D.E. & Reddy, J.K. (1977). Absence of increased carnitine acetyl transferase activity in the liver with proliferation of smooth endoplasmic reticulum. Biochem. Pharmacol., 26, 1451-1452.
39.
Moody, D.E. & Reddy, J.K. (1978a). Hepatic peroxisome (microbody) proliferation in rat fed plasticizers and related compounds. Toxicol. Appl. Pharmacol., 45, 497-504.
40.
Moody, D.E. & Reddy, J.K. (1978b). The hepatic effects of hypolipidemic drugs (clofibrate, nafenopin, tibric acid and Wy-14,643) on hepatic peroxisome and peroxisome associated enzymes. Am. J. Pathol., 90, 435-445.
41.
Neat, C.E. & Osmundsen, H. (1979). The rapid preparation of peroxisomes from rat liver by using a vertical rotor. Biochem. J., 180,445-448.
42.
Novikoff, A.B. & Goldfischer, S. (1969). Visualization of peroxisomes (microbodies) and mitochondria with diaminobenzidine. J. Histochem. Cytochem., 17, 675-680.
43.
Oliver, M.F., Heady, J.A., Morris, J.N. & Cooper, J. (1980). WHO cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: Mortality follow-up. Lancet, 2, 379-385.
44.
Osumi, T. & Hashimoto, T. (1978). Enhancement of fatty acyl-CoA oxidizing activity in rat liver peroxisomes by di-(2-ethylhexyl)phthalate. J. Biochem. (Tokyo), 83, 1361-1365. Reddy, J.K. (1974). Hepatic microbody proliferation and catalase synthesis induced by methyl clofenapate, a hypolipidemic analog of CPIB. Am. J. Pathol., 75,103-118.
45.
Reddy, J.K. (1977). Induction of hepatic peroxisomes and peroxisome-associated enzymes: an evaluative test for hypolipidemic compounds. In Proc. Int. Conf. Atherosclerosis, Milan , Nov. 9-12.
46.
Reddy, J.K. (1980). Peroxisome proliferative and carcinogenic effects of hypolipidemic drugs. In Drugs Affecting Lipid Metabolism (R. Fumagalli, D. Kritchevsky and R. Paoletti, eds.). pp. 301-310. Amsterdam, Elsevier/North Holland Biomedical Press .
47.
Reddy, J.K., Arzarnoff, D.L. & Hignite, C.E. (1980). Hypolipidemic peroxisome proliferators form a novel class of chemical carcinogens. Nature, 283, 397-398.
48.
Reddy, J.K., Azarnoff, D.L. & Sirtori, C.R. (1978). Hepatic peroxisome proliferation: Induction by BR-931, a hypolipidemic analog of Wy-14,643. Arch. Int. Pharmacodyn. , 234, 4-14.
49.
Reddy, J.K. & Krishnakantha, T.P. (1975). Hepaticperoxisome proliferation: Induction by two novel compounds structurally unrelated to clofibrate. Science, 190, 787-789.
50.
Reddy, J.K. & Kumar, N.S. (1979). The peroxisome proliferation associated polypeptide in rat liver. Biochem. Biophys. Res. Commun., 77, 824-829.
51.
Reddy, J.K., Lalwani, N.D., Reddy, M.K. & Qureshi, S.A. (1982a). Excessive accumulation of autofluorescent lipofuscin in the liver during hepatocarcinogenicity by methyl clofenapate and other hypolipidemic peroxisome proliferators. Cancer Res., 42, 259-266.
52.
Reddy, J.K., Moody, D.E., Azarnoff, D.L. & Rao, M.S. (1976). Di-(2-ethylhexyl)-phthalate: An industrial plasticizer induces hypolipidemia and enhances hepatic catalase and camitine acetyltransferase activities in rats and mice. Life Sci., 18, 94-96.
53.
Reddy, J.K. & Qureshi, S.A. (1979). Tumorigenicity of the hypolipidemic peroxisome proliferators ethyl-α-p-chlorophenoxy-isobutyrate (clofibrate) in rats . Brit. J. Cancer, 40, 476-482.
54.
Reddy, J.K., Rao, M.S., Azarnoff, D.L. & Sell, S. (1979). Mitogenic and carcinogenic effect of hypolipidemic peroxisome proliferators [4-chloro-6(2,3-xylidino)-2-pyrimidylthio]acetic acid (Wy-14,643) in rat and mouse liver. CancerRes., 39, 152-161.
55.
Reddy, J.K. & Svoboda, D. (1973). Microbody (peroxisome) matrix transformation into tubular structures. Virch. Arch. B., 14, 83-92.
56.
Reddy, J.K. & Warren, J.R. (1981). Toxicological implications of hepatic peroxisome proliferation: possible role of oxygen radical toxicity in hypolipidemic drug induced carcinogenesis. Toxicologist, 1, 131. (Abstract).
57.
Reddy, J.K. Warren, J. R., Reddy, M.K. & Lalwani, N.D. (1982b). Hepatic and renal effect of peroxisome proliferators: Biological implications. Ann. N.Y. Acad. Sci.638, (in press).
58.
Reddy, M.K., Hollenberg, P.F. & Reddy, J.K. (1980). Partial purification and immunoreactivity of an 80000 molecular weight polypeptide associated with peroxisome proliferation in rat liver. Biochem. J., 188, 731-740.
59.
Reddy, M.K., Qureshi, S.A., Hollenberg, P.F. & Reddy, J.K. (1981). Immunochemical identity of peroxisomal enoyl-CoA hydratase with the peroxisome-proliferation associated 80000 mol. wt. polypeptide in rat liver. J. Cell Biol., 89, 406-417.
60.
Rodney, G., Uhtendorf, P. & Maxwell, R.E. (1976). The hypolipidaemic effect of gemfibrozil (CI-719) in laboratory animals. Proc. Roy. Soc. Med., 69, 6-10.
61.
Rossner, S. & Oro, L. (1978). Effects on serum lipoproteins of procetofene in hyperlipoproteinemia: Dose-response studies and comparison with clofibrate . In Intern. Conf. on Atherosclerosis (L. A. Carlson, R. Paoletti , C. R. Sirtori and G. Weber, eds.). pp. 135-140. New York, Raven Press.
62.
Roze, C., Cuchet, P., Souchard, M., Vaille, C. & Debray, C. (1977). The effects of tiadenol, clofibrate and clofibride on bile composition. Eur. J. Pharmacol., 43, 57-64.
63.
Sirtori, C.R., Tremoli, E. & Paoletti, R. (1980). New strategies in the development of anti-atherosclerotic drugs. Artery, 8, 507-518.
64.
Sirtori, C.R. (1981). Mechanism of action of clofibrate. Lancet, i, 1362.
65.
Solberg, P.M., Aas, M. & Daae, L.N.W. (1972). The activity of the different carnitine acetyl transferases in the liver of clofibrate fed rats. Biochim. Biophys. Acta, 280, 434-439.
66.
Stegmeier, K., Stork, H., Lenz, H., Leuschner, F. & Liede, V. (1980). Pharmacology and mode of action of bezafibrate in animals. In Lipoproteins and Coronary Heart Disease (H. Greten, P. D. Lang and G. Schettler, eds.). pp. 76-82. New York, Gerhard Witzstrock Publishing House.
Svoboda, D.J. (1978). Unusual responses of rat hepatic and renal peroxisomes to RMI-14,514 a new hypolipidemic agent. J. Cell Biol., 78, 810-822.
69.
Svoboda, D.J. & Azarnoff, D.L. (1966). Response of hepatic microbodies to a hypolipidemic agent ethylchlorophenoxyisobutyrate (CPIB). J. Cell Biol., 30, 442-450.
70.
Svoboda, D.J. & Azarnoff, D.L. (1979). Tumors in male rats fed ethylchlorophenoxyisobutyrate a hypolipidemic drug. CancerRes. , 39, 3419-3428.
71.
Thorp, J.M. (1970). Hypocholesterolemic and other effects of methyl clofenapate, a novel derivative of clofibrate. In Atherosclerosis: Proceedings of the Second International Symposium (R. J. Jones, ed.). pp. 541-544. New York, Springer-Verlag.
72.
Yarrington, J.T., Sprinkle, D.L., Loudy, D.E., Kariya, T. & Gibson, J.P. (1981). Effect of the hypolipidemic drug RMI 14-514 on hepatic ultrastructure of rats. Exp. Mol. Pathol., 34, 307-322.
